FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1708-1709 December 6, 2001 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: The review article by FitzGerald and Patrono (Aug. 9 issue)¹ on the coxibs, selective inhibitors of cyclooxygenase-2 (COX-2), included a table listing pharmacokinetic and metabolic features as well as drug interactions. According to the table, in patients taking warfarin, rofecoxib causes a 10 percent increase in the international normalized ratio (INR), but there is no interaction between celecoxib and warfarin.

Since the introduction of celecoxib in Australia in October 1999, the Adverse Drug Reactions Advisory Committee has received 2218 reports of suspected adverse drug reactions. Of these, 21 involved an increase in INR values in patients treated . . . [Full Text of this Article]

References

This article has been cited by other articles:

• SPINK, M., BAHN, S., GLICKMAN, R. (2005). Clinical implications of cyclo-oxygenase-2 inhibitors for acute dental pain management: Benefits and risks. Journal of the American Dental Association 136: 1439-1448 [Abstract] [Full Text]  
• Mulshine, J. L., Atkinson, J. C., Greer, R. O., Papadimitrakopoulou, V. A., Van Waes, C., Rudy, S., Martin, J. W., Steinberg, S. M., Liewehr, D. J., Avis, I., Linnoila, R. I., Hewitt, S., Lippman, S. M., Frye, R., Cavanaugh, P. F. Jr. (2004). Randomized, Double-Blind, Placebo-Controlled Phase IIB Trial of the Cyclooxygenase Inhibitor Ketorolac as an Oral Rinse in Oropharyngeal Leukoplakia. Clin. Cancer Res. 10: 1565-1573 [Abstract] [Full Text]